coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Oldham Central PCN, Oldham (LAD) · Health Inequalities Profile

    PCN U14327 · NHS Greater Manchester Integrated Care Board · 11 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    65,449

    Registered population

    62.3% aged 18–64

    10.2%

    Aged 65+

    ICB 14.9% · England 17.9%

    94.2%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~49,305

    Core20 residents (est.)

    Resident basis; registered basis ~62,783 · see page 3

    8,214

    Hypertension register

    +1.53% in 3 yrs · England +5.60%

    868

    SMI register

    29.8% of Oldham (LAD)'s

    1,420

    COPD register

    Reviews +12.08% in 3 yrs

    Forecast to 2030

    8,499

    Hypertension patients, 2030

    +285 on today

    86.1%

    QRISK ≥20% on statins, 2030

    +3.90pp over 3 yrs

    2.5%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    12.6 pp
    Preschool MMR2 and booster uptake trails MMR1.

    Age-5 MMR1 is 93.4%, but MMR2 is 80.8% (14.2 pp below the 95.0% target, a 12.6 pp same-cohort gap) and 4-in-1 is 79.5%.

    -0.7%
    Under-80 BP and diabetes HbA1c control lag.

    Under-80 BP control fell 0.7% (England +3.2%) to 67.3%, hypertension prevalence is 12.0% (+1.5%), and non-frail diabetes HbA1c <= 58 mmol/mol is 54.4%.

    +19.0%
    Respiratory reviews and lipid therapy exceed England.

    Asthma annual reviews rose +19.0% (England +4.4%) to 76.8%, COPD reviews reached 83.2% (England 76.4%), and QRISK >= 20% lipid therapy reached 77.7%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Registered population is young with 27.5% aged 0-17 against 19.6% across England

    Oldham Central PCN serves 65,449 registered patients. The population is young: 27.5% (18,022 patients) are aged 0-17, exceeding Oldham LAD (24.6%), NHS Greater Manchester ICB (21.8%) and England (19.6%). Patients aged 65+ comprise 10.2% (6,652 patients), below Oldham LAD (13.2%), the ICB (14.9%) and England (17.9%). Census usual residents include 0.4% Roma (Oldham LAD 0.2%, ICB 0.1%, England 0.2%) and 0.1% Gypsy or Irish Traveller (Oldham LAD 0.1%, ICB 0.1%, England 0.1%). Registered age counts and resident Census bases cannot be directly combined for service planning.

    Age profile

    0–1727.5%
    18–6462.3%
    65+10.2%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Oldham (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Oldham LA)2,1412,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)82.4%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)54.4%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Oldham LA)1,1151,0219552024/25
    Falls deaths, all ages, per 100,000 (Oldham LA)20.918.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    With 94.2% in Core20, deprivation is deeply concentrated across all eleven practices

    The PCN has 94.2% of registered patients in the Core20 cohort, compared with 56.7% in Oldham, 40.7% across NHS Greater Manchester ICB, and 21.0% in England, with an average IMD decile of 1.6 (Oldham 3.6, England 5.5). Five practices record 100.0% Core20 concentration, but Glodwick Medical Practice holds the highest volume at 10,529 estimated patients. Registered practice estimates sum to 62,783 (weighted share 95.9%), differing from the 49,305 resident LSOA deciles 1 and 2 estimate. Reconciling registered lists and resident counts is essential before deploying targeted outreach across practices.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Chowdhury100.0% · 5,866 patients
    Oldham100.0% · 3,807 patients
    Jalal100.0% · 2,922 patients
    Perkins100.0% · 2,417 patients
    Lindley House100.0% · 4,818 patients
    John Street96.9% · 4,756 patients
    Glodwick Medical96.9% · 10,529 patients
    Alexandra Group95.8% · 6,799 patients
    Greenbank Medical94.8% · 8,935 patients
    Hopwood House90.5% · 5,923 patients
    St Mary's88.7% · 6,011 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    868

    SMI register

    1.27% recorded prevalence

    554

    Learning disability register

    0.81% recorded prevalence

    19

    Care homes, 665 beds

    In the PCN catchment

    9.8%

    Provide unpaid care

    Oldham (LAD), Census 2021

    For OLDHAM CENTRAL PCN, recorded severe mental illness QOF prevalence is 1.3% (868 patients; England 1.0%), and learning disability QOF prevalence is 0.8% (554 patients; England 0.6%). The PCN catchment includes 19 care homes with 665 beds. Higher crude recorded prevalence than national comparators may reflect higher local review demand, though register prevalence does not establish unmet need.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 1.3% (England 1.0%). Published individual elements exceed England, with 86.2% BMI recording (England 82.1%) and 84.8% blood pressure checks (England 83.4%); separate element recording does not confirm completed full physical health checks.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    8,214

    Hypertension register

    +1.53%

    Register growth, 3 yrs

    Oldham (LAD) +4.38% · England +5.60%

    −0.47pp

    BP control, under 80

    ≤140/90 · −0.21pp aged 80+

    +285

    More patients by 2030

    Forecast 8,499 (12.41%)

    Hypertension case-finding and control

    Hypertension prevalence is 12.0% (8,214 patients), below Oldham (14.7%) and England (15.2%), with three-year growth of +1.5% trailing England (+5.6%). While recent blood pressure checks reach 91.8% (England 90.0%), blood pressure control to <= 140/90 mmHg for patients under 80 is 67.3% (England 67.8%), falling 0.7% over three years (England +3.2%). Treatment to target is 69.5% (England 70.3%). Unadjusted prevalence does not establish unmet need, and the implied register base differs from the 65,449 list size. Lower blood pressure control under 80 than across England may indicate a need to prioritise systematic recall and medication titration for patients whose blood pressure remains above threshold.

    Lipids and statins

    Lipid-lowering therapy reaches 77.7% for patients with QRISK >= 20% (England 63.6%), 79.8% in CKD (England 70.3%), and 83.2% in diabetes without cardiovascular disease (England 73.2%). Higher lipid-lowering coverage than England across all risk cohorts provides an opportunity to maintain strong primary prevention reach.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026124,779£1.30£1.94£1.86£162,213
    Cardiovascular (all), 2025140,493£2.62£3.15£3.33£368,092

    In 2026, the PCN prescribed 124,779 lipid-regulating drug items at £1.30 per item, below Oldham (£1.53) and England (£1.86), spending £69,876 less than at England's unit cost. Unit cost does not measure prescribing efficiency. Lower unit costs than England reflect lower spend per item across prescribed items, though unit cost does not establish prescribing efficiency.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +19.01%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −1.59%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.0% (England 6.6%), while annual reviews rose +19.0% over three years (England +4.4%) to 76.8% (England 65.7%), though an estimated 1,010 patients on the 4,344 register lack a recorded review. Second-hand smoke status was recorded for 92.0% of asthma patients aged 6-19 (England 78.8%), but asthma prescribing for ages 5-19 was 1,270 items per 1,000 (England 1,488). COPD prevalence is 2.1% (England 1.9%) with reviews reaching 83.2% (England 76.4%), up +12.1% over three years (England +2.8%).

    Cancer register and children's immunisation

    Cancer prevalence is 2.1% (England 3.8%) with 1,453 patients. Childhood immunisation trails national benchmarks and the 95.0% target. At 12 months, 6-in-1 coverage is 85.8% (England 91.0%), 9.2 pp below the target. At age 5, first-dose MMR reaches 93.4% (England 91.7%), but second-dose MMR falls to 80.8% (England 82.8%), a 12.6 pp dose contrast, while 4-in-1 booster coverage is 79.5% (England 80.9%), leaving preschool booster protection incomplete.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months85.8%

    England 91.0%

    6-in-1 complete primary course at 24 months89.0%

    England 92.2%

    MMR dose 1 at 24 months88.1%

    England 88.3%

    MMR dose 2 at age 580.8%

    England 82.8%

    4-in-1 pre-school booster at age 579.5%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 with a known stage, with 70.8% known-stage coverage), showing a distance of -19.4 pp to the 75.0% national ambition by 2028 and requiring about 2,270 extra early-stage cases annually across the ICB. At PCN level, cervical screening for women aged 25-49 is 57.2% (England 66.8%), with a 3-year change of -5.9% (England -1.0%), and breast screening coverage is 59.0% (England 69.9%). Crude PCN cancer prevalence is 2.1% (England 3.8%). Lower screening coverage than England across cervical and breast programmes highlights priority areas for PCN recall systems.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Northern Care Alliance NHS Foundation Trust, the distance to the 85.0% 62-day referral to treatment standard is -6.4 pp, while NHS Greater Manchester Integrated Care Board shows a distance of -9.3 pp. On the 28-day faster diagnosis standard (75.0%), the distance is 0.2 pp for the trust and 4.5 pp for the ICB. On the 31-day combined treatment standard (96.0%), the distance is -1.5 pp for the trust and 0.5 pp for the ICB. These provider and ICB measures describe wider system waits, not PCN performance. Secondary care treatment delays at provider level highlight the importance of high-quality urgent.

    Pathways within standard (%)Northern Care AllianceTameside and Glossop Integrated CareManchesterGreater Manchester ICBEngland
    28-day faster diagnosis (75%)75.2082.4880.0679.5379.32
    31-day treatment (96%)94.5496.2592.5496.4992.50
    62-day referral to treatment (85%)78.6576.7772.8575.7371.16
    Diagnostic waits over 6 weeks (%)Northern Care AllianceTameside and Glossop Integrated CareManchesterEngland
    MRI5.090.0011.6821.40
    CT4.100.1814.669.92
    Echocardiography31.480.004.9128.48
    Colonoscopy40.041.514.5130.83
    Gastroscopy36.485.4529.3529.02
    All 15 DM01 tests15.710.808.9823.14
    Community services activityOldham residentsGreater Manchester ICB
    Care contacts71,440573,310
    Referrals8,26094,470
    Patients with a contact17,500183,535

    Community services (residents of Oldham), Jun 2026 (provisional). Provisional community services data for Oldham residents records 71,440 total contacts, with adults aged 65 and over accounting for 35,720 contacts, representing 50% of all activity. These figures reflect borough-wide resident contacts rather than PCN-level delivery. With adults aged 65 and over representing 50% of community contacts, primary care and community teams must coordinate closely around older patients.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Perkins Practice96100.059.7%64.0%86.8%
    St Mary's9788.766.4%82.9%85.9%
    John Street7796.948.5%72.7%80.2%
    Oldham86100.060.8%63.4%76.6%
    Hopwood House11190.549.6%65.2%76.5%
    Alexandra Group9395.840.3%61.9%74.1%
    Jalal Practice81100.051.7%60.4%73.8%
    Lindley House83100.046.0%86.2%72.6%
    Chowdhury58100.038.6%91.7%63.2%
    Greenbank Medical7794.843.5%66.6%60.9%
    Glodwick Medical9196.944.0%88.3%59.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNOldham (LAD)AssetPCNOldham (LAD)
    Care homes (catchment)19 (665 beds)n/aSchools (catchment)89n/a
    Children's centres816Places of worship50127
    Libraries410Primary schools (LA maintained)942
    Primary academies1541Special schoolsn/a1

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Preschool booster and MMR2 catch-up

    At age 5 (cohort 229), MMR1 is 93.4% (England 91.7%), while MMR2 is 80.8% (England 82.8%, 14.2 pp below the 95.0% target; 12.6 pp below MMR1) and 4-in-1 is 79.5% (15.5 pp below 95.0%). Moderate effort to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 2

    Hypertension BP control and case-finding

    Under-80 BP control (<= 140/90 mmHg) is 67.3% (England 67.8%), with 3-year change of -0.7% (England +3.2%). Hypertension prevalence is 12.0% (8,214 patients; England 15.2%), growing +1.5% (England +5.6%). For discussion: practices could run pharmacist-led titration reviews for under-80s above 140/90 mmHg alongside opportunistic BP checks in high-Core20 practices. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Asthma annual review and prescribing follow-up

    Asthma annual reviews rose +19.0% over 3 years to 76.8% (England 65.7%), leaving an estimated 1,010 (about 1,000) of 4,344 register patients without a recorded review in the last 12 months. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Paediatric access and capacity review (p2)Aged 0-17Medium Term Planning Framework 2026 · Neighbourhood health frameworkPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check coordination (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall and titration audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Preschool booster recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Preschool booster and MMR2 catch-up (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 2 · Hypertension BP control and case-finding (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Asthma annual review and prescribing follow-up (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15